8 February 2013

The article integrates the MRI data available from 3 patients in the SYM-08-001 (first-in-man) study into a validated mathematical model to reconstruct the patients’ left ventricular geometry before and 3- and 6 months after Algisyl treatment. The model quantifies cardiac function using end-diastolic volume (EDV), end-systolic volume (ESV), regional wall thickness, sphericity index and regional myofiber stress. The conclusion states the following:

Our results support the novel concept that the injection of material into the LV free-wall with CABG is an effective strategy for inducingLV reverse remodeling that improves the LV cardiac function and results in a decreased myofiber stress. Although the power of this finding is limited by the small sample size, the effects of this treatment are interesting and remarkable. The results of a recently initiated, randomized,controlled study to evaluate Algisyl-LVR™ solely as a method of LV augmentation for patients with severe heart failure (AUGMENT-HF) should provide definitive conclusions about the clinical benefits of Algisyl-LVR™ therapy.

The article is available from ScienceDirect here

For those interested in the mathematical model itself, an additional peer-reviewed publication in video format is available at the Journal of Visualized Experiments (JoVE), here

9 October 2012

LoneStar Heart Inc. today announced the completion of an up to $20 million milestone-based equity financing to support the clinical testing and regulatory clearance of its lead product, Algisyl-LVR, a single-use, self-gelling biopolymer implanted into the heart’s left ventricle during surgery for the treatment of advanced heart failure. Themes Investment Partners (“Themes”), a Hong Kong-based private equity fund focused on China markets, led the round. The new financing brings up to $35 million in equity funding since the company’s founding in June 2010.

Click here to read the complete release. 

2 October 2012

Press release – LoneStar Heart Inc. today announced the first patient was treated in the company’s international multi-center AUGMENT-HF clinical trial of Algisyl-LVR at IRCCS San Raffaele Pisana and at Umberto I Policlinico, both located in Rome, Italy.

Click here to read the complete release.

28 August 2012

LoneStar Heart Presents Abstract at the Annual Meeting of the Heart Failure Society of America. The text of the abstract is available from the Journal of Cardiac Failure here

29 May 2012

The announcement follows a study conducted by researchers at the University of Texas Southwestern Medical Center (UT Southwestern), published in the on-line May 13th issue of the journal Nature, demonstrating feasibility of the approach. The company has acquired exclusive worldwide rights to the new technology.

 

 

28 March 2012

Data from LoneStar Heart’s first-in-man study has recently been published in Cell Transplantation. Free full text for Lee et. al. “Polymer-based restoration of left ventricular mechanics” is available here.

26 April 2012

To learn more about Texans for Stem Cell Research, check their website at http://www.txstemcell.org/